When was LikeMinds founded?

LikeMinds was founded in 2008 and raised its 1st funding round 10 years after it was founded.

Where is LikeMinds located?

LikeMinds is headquartered in Boston, United States.

How many employees does LikeMinds have?

As of Jul 31, 2026, the latest employee count at LikeMinds is 11.

Is LikeMinds a funded company?

LikeMinds is a funded company, having raised a total of $6.37M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Sep 12, 2018.

When was the latest funding round of LikeMinds?

LikeMinds' latest funding was a $***** Series A round on Jun 14, 2021, with participation from 0 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $3.67B in funding in 2026 to date.

Where does LikeMinds rank among its competitors?

LikeMinds ranks 8th amongst 52 active competitors, of which 13 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Amprion, which secured an undisclosed amount in Jul, 2026.

Who are the top competitors of LikeMinds?

LikeMinds' top competitors include Octave Bioscience, Amprion and PeopleBio R&D. Among them, Amprion secured the most recent funding round in July, 2026.

LikeMinds - 2026 Company Profile, Funding & Competitors

Company Details

Provider of dopamine transporter imaging agent for diagnosis of neurodegenerative diseases. The company uses its technology to recognize a certain kind of patient’s tremor, which helps in understanding the type of disease. DaT2020, their flagship product, is a SPECT imaging agent that has selectivity for neuronal dopamine transporters that helps in better visualization information.

Website: likeminds.com
Social
Email ID: *****@likeminds.com
Phone Number: +1 **********

Key Metrics

Founded Year

2008

Location

Boston, United States

Stage

Series A

Total Funding

$6.37M in 2 rounds

Latest Funding Round

Series A, Jun 14, 2021, $*****

Ranked

8^th among 52 active competitors

Employee Count

11 as on Jul 31, 2026

Similar Companies

Octave Bioscience & 66 more

View LikeMinds' full profile

LikeMinds has raised a total funding of $6.37M over 2 rounds. Its first funding round was on Sep 12, 2018.

Here is the list of recent funding rounds of LikeMinds:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 14, 2021	2053415	Series A	2009465	4307033	9308162	9844250
Sep 12, 2018	5946531	Series A	4192201	3426218	3790776	4051327

Access funding benchmarks and valuations. Sign up today!

View details of LikeMinds's funding rounds and investors

LikeMinds' employee count trend

LikeMinds has 11 employees as of Jul 26. Here is LikeMinds's employee count trend over the years:

Uncover LikeMinds' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of LikeMinds include Octave Bioscience, Amprion and PeopleBio R&D. Here is the list of Top 10 competitors of LikeMinds, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Octave Bioscience 2014, Menlo Park (United States), Series C	Provider of AI-based molecular diagnostic tools for neurodegenrative diseases	$124M	Novartis, BVF & 14 others	65/100
2nd	Amprion 2006, Houston (United States), Series B	Revolutionizing neurodegenerative disease diagnosis with advanced α-synuclein detection technology	$11.8M	Formationve, Lilly & 3 others	56/100
3rd	PeopleBio R&D 2002, Seongnam-si (South Korea), Public	Immunoassays for early detection of neuro-degenerative diseases	-	DT&Investment, GNTech Venture Capital & 12 others	48/100
4th	Nanostics 2017, Edmonton (Canada), Seed	Developer of diagnostic tests to detect cancers, cardiovascular and neurodegenerative diseases	-	indyRIOT	40/100
5th	Cytox 2007, Oxford (United Kingdom), Series B	Developer for prognostic tests for assessing the risk of dementia	$12.1M	Maven Capital Partners, Northwest Fund & 22 others	39/100
6th	Alseres Pharmaceuticals 1972, Auburndale (United States), Public	Therapeutic and diagnostic products for disorders in the central nervous system (CNS)	$4M	Ingalls and Snyder	35/100
7th	Durin Life Sciences 2010, United States, Acquired	Early disease detection blood tests for Alzheimer's and Parkinson's	$5.5M	-	34/100
8th	LikeMinds 2008, Boston (United States), Series A	Provider of dopamine transporter imaging agent for diagnosis of neurodegenerative diseases	$6.37M	-	34/100
9th	Durin Technologies 2010, Camden (United States), Series B	Developer of the diagnostic test for neurodegenerative diseases	$8.05M	Breakthrough Diagnostics	32/100
10th	Gene Solutions 2006, Charlottesville (United States), Series A	Pioneering mitochondrial medicine, developing therapeutics for neurodegenerative and muscular diseases	$6.33M	-	32/100